Novel serum biomarkers for erythropoietin use in humans: a proteomic approach.
Erythropoietin (Epo) is produced primarily in the kidneys upon low blood oxygen availability and stimulates erythropoiesis in the bone marrow. Recombinant human Epo (rHuEpo), a drug developed to increase arterial oxygen content in patients, is also illicitly used by athletes to improve their endurance performance. Therefore, a robust and sensitive test to detect its abuse is needed. The aim of the present study was to investigate potential human serum biomarkers of Epo abuse employing a proteomic approach. Eight healthy male subjects were injected subcutaneously with rHuEpo (5,000 IU) every second day for a 16-day period. Serum was collected before starting the treatment regime and again at days 8 and 16 during the treatment period. Samples were homogenized and proteins separated by two-dimensional gel electrophoresis (2DE). Spots that changed significantly in response to rHuEpo treatment were identified by mass spectrometry. Both the number of reticulocytes and erythrocytes increased throughout the study, leading to a significant increase in hematocrit and hemoglobin content. In addition, transferrin levels increased but the percentage of iron bound to transferrin and ferritin levels decreased. Out of 97 serum proteins, seven were found to decrease significantly at day 16 compared with pre-Epo administration, and were identified as four isoforms of haptoglobin, two isoforms of transferrin, and a mixture of hemopexin and albumin. In support, total serum haptoglobin levels were found to be significantly decreased at both days 8 and 16. Thus a 2DE proteomic approach for discovery of novel markers of Epo action appears feasible.
Christensen
Britt
B
Department of Endocrinology and Internal Medicine, NBG/THG, Aarhus University, Denmark.
Sackmann-Sala
Lucila
L
Cruz-Topete
Diana
D
Jørgensen
Jens Otto L
JO
Jessen
Niels
N
Lundby
Carsten
C
Kopchick
John J
JJ
D000328:Adult; D001798:Blood Proteins / Q000032:analysis*; D004300:Doping in Sports / Q000517:prevention & control*; D004921:Erythropoietin / Q000097:blood*; D006801:Humans; D008297:Male; D058573:Performance-Enhancing Substances / Q000097:blood*; D020543:Proteome / Q000032:analysis*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D015813:Substance Abuse Detection / Q000379:methods*
D001798:Blood Proteins; D058573:Performance-Enhancing Substances; D020543:Proteome; D004921:Erythropoietin